Loading clinical trials...
Loading clinical trials...
Phase I Clinical Trial of Safety, Tolerance and Immunogenicity of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
Conditions
Interventions
Experimental Vaccine 1
Experimental Vaccine 2
+2 more
Locations
1
China
Ning ling Center for Disease Control and Prevention
Shangqiu, Henan, China
Start Date
June 18, 2022
Primary Completion Date
February 28, 2024
Completion Date
February 28, 2024
Last Updated
January 16, 2026
NCT06402318
NCT06927622
NCT05706454
NCT04193878
NCT05531032
NCT04466098
Lead Sponsor
National Vaccine and Serum Institute, China
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions